Feed ATAI
AT

Atai Life Sciences N.V. ATAI · NASDAQ

$7.35 +0.68% (+$0.05)

Market cap
$2.72B
Enterprise value
$2.55B
P/E
-
Forward P/E
-
PEG
-
P/S
607.9x
P/FCF
-
EV/EBITDA
-
ROIC
-61.3%
Bruto marža
86.3%
Neto marža
-14,938.4%
Dividend yield
91.84%
Payout ratio
-
Neto dolg/EBITDA
-
Beta
1.55
Free float
54.2%

O podjetju

Atai Life Sciences N.V. (ATAI) is a biotechnology company focused on research and development of novel therapeutic approaches in the field of mental health and psychiatric disorders. The company focuses on innovative therapies and drugs that have the potential to treat or improve the lives of people suffering from various mental illnesses, including depression, anxiety, post-traumatic stress disorder, addictions, and other disorders. Atai Life Sciences actively collaborates with other research institutions and biotechnology companies and invests in projects with the hope of discovering new treatment options. Their goal is to bring new drugs and therapies to the market that can make a significant difference for patients with mental disorders. Atai Life Sciences N.V. (ATAI) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focusing on innovative therapeutic approaches in the field of mental health.

Sector

Healthcare

Industry

Biotechnology

CEO

Srinivas G. Rao

Employees

99

Headquarters

New York

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

  • Kaj govori v prid: Prihodki so v zadnjih 3 letih rasli za 160 % letno.
  • Na kaj bodite pozorni: Analitiki v tem poslovnem letu pričakujejo padec prihodkov za 47 %.
  • Na kaj bodite pozorni: Napovedi dobička ni dosegla 4-krat v zadnjih 8 četrtletjih.

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

  • Na kaj bodite pozorni: Podjetje je v zadnjih 12 mesecih poslovalo z izgubo.

Finančno zdravje

Ali zmore svoj dolg?

  • Kaj govori v prid: Ima več denarja kot dolga: $168,8M proti $4,29M.

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe.